4981-83-3

Usage

Uses

Used in Pharmaceutical Industry:
Ethanol, 2-(phenylmethoxy)-, 4-methylbenzenesulfonate is used as a protecting group for [application type] in the pharmaceutical industry for [application reason] the acid-labile benzyl group, which can be selectively removed under acidic conditions, allowing for controlled drug release or activation.
Used in Drug Delivery Systems:
In the field of drug delivery, Ethanol, 2-(phenylmethoxy)-, 4-methylbenzenesulfonate is used as a component of drug conjugates for [application reason] its ability to improve the solubility and stability of drugs in aqueous environments. The tosyl group serves as a linker that can be cleaved under specific conditions, enabling targeted drug release.
Used in Chemical Synthesis:
Ethanol, 2-(phenylmethoxy)-, 4-methylbenzenesulfonate is used as an intermediate in chemical synthesis for [application reason] its functional groups, which can be utilized in various reactions to produce a range of compounds with different properties and applications.
Used in Research and Development:
In research and development, Ethanol, 2-(phenylmethoxy)-, 4-methylbenzenesulfonate is used as a model compound for [application reason] studying the effects of PEGylation on the properties and behavior of molecules, as well as for developing new methods and techniques in chemical synthesis and drug delivery.

Upstream product

• 622-08-2 2-Benzyloxyethanol 
• 98-59-9 p-toluenesulfonyl chloride 
• 30379-55-6 benzyloxyacetic acid 
• 100-44-7 benzyl chloride 
• 100-39-0 benzyl bromide 
• 20194-18-7 sodium phenyl-methanolate 

Downstream Products

• 6992-24-1 Toluene-4-sulfonate3-(2-benzyloxy-ethyl)-2-methyl-4,5-dihydro-thiazol-3-ium; 
• 727-18-4 diethyl <2-(benzyloxy)ethyl>phosphonate 
• 151331-33-8 1,9-(dibenzyloxy)-5,5-diethyl-3,7-dioxanonane 
• 87105-08-6 1-Phenyl-2,5-dioxahexadecan 
• 131354-77-3 C₃₆H₃₄O₆ 
• 82264-96-8 2,2'-<1,2-Ethandiyloxybis(oxy-2,1-phenylenoxy)>bisethanol-dibenzylether 
• 113518-40-4 (1S,2R,3R,5R,6S,7S)-6-(2-Benzyloxy-ethoxy)-4,8-dioxa-tricyclo[5.1.0.0^3,5]octan-2-ol 
• 113518-41-5 (1R,2S,3S,5R,6S,7S)-2,6-Bis-(2-benzyloxy-ethoxy)-4,8-dioxa-tricyclo[5.1.0.0^3,5]octane 
• 131354-79-5 C₄₀H₃₈O₆ 
• 131354-78-4 2,3-Bis-[2-(2-benzyloxy-ethoxy)-phenoxy]-naphthalene 
• 131354-80-8 C₄₄H₃₈O₆ 
• 131354-81-9 C₄₈H₄₀O₆ 
• 87104-73-2 15,15-Bis<2-(benzyloxy)ethoxy-methyl>-1,4,7,10,13-pentaoxacyclohexadecan 
• 142723-22-6 2-(2-Benzyloxy-ethoxy)-5-decyl-benzoic acid methyl ester 

Relevant academic research and scientific papers

Formation of ether-functionalized ionic-liquid-based aqueous two-phase systems and their application in separation of protein and saccharides

Ionic-liquid (IL)-based aqueous two-phase systems (ATPSs) have attracted much attention in the separation technology. In this work, we synthesized five novel ether-functionalized ILs and studied their applications in ATPS formation. The phase diagrams for

COMPOUNDS AND METHODS FOR TARGETED DEGRADATION OF KRAS

Bifunctional compounds, which find utility as modulators of Kirsten ras sarcoma protein (KRas or KRAS), are described herein. In particular, the hetero-bifunctional compounds of the present disclosure contain on one end a moiety that binds to the Von Hippel-Lindau E3 ubiquitin ligase and on the other end a moiety which binds KRas, such that the target protein is placed in proximity to the ubiquitin ligase to effect degradation (and inhibition) of target protein. The heterobifunctional compounds of the present disclosure exhibit a broad range of pharmacological activities associated with degradation/inhibition of target protein. Diseases or disorders that result from aberrant regulation of the target protein are treated or prevented with compounds and compositions of the present disclosure.

3-(5-HYDROXY-1-OXOISOINDOLIN-2-YL)PIPERIDINE-2,6-DIONE DERIVATIVES AND USES THEREOF

The present disclosure provides a compound of Formula (I′): or a pharmaceutically acceptable salt, hydrate, solvate, prodrug, stereoisomer, or tautomer thereof, wherein Rx, X1, X2, and R1 are as defined herein, and methods of making and using same.

Preparation method of high purity 2-benzyloxy bromoethane

The invention relates to a preparation method of an important intermediate 2-benzyloxy bromoethane (formula I) of umeclidinium bromide. The conditions of the preparation method are mild and controllable; post-treatment is simple; yield is high; and the purity of prepared 2-benzyloxy bromoethane is high.

MODULATORS OF PROTEOLYSIS AND ASSOCIATED METHODS OF USE

The present disclosure relates to bifunctional compounds, which find utility as modulators of Kirsten rat sarcoma protein (target protein). In particular, the present disclosure is directed to bifunctional compounds, which contain on one end a Von Hippel-Lindau, cereblon, Inhibitors of Apotosis Proteins or mouse double-minute homolog 2 ligand which binds to the respective E3 ubiquitin ligase and on the other end a moiety which binds the target protein, such that the target protein is placed in proximity to the ubiquitin ligase to effect degradation (and inhibition) of target protein. The present disclosure exhibits a broad range of pharmacological activities associated with degradation/inhibition of target protein. Diseases or disorders that result from aggregation, accumulation, and/or overactivation of the target protein are treated or prevented with compounds and compositions of the present disclosure.

Compound, the liquid crystal composition, high molecular material and film

A liquid crystal composition comprising a compound represented by the following formula has sufficient solubility and a wide usable concentration range, and exhibits excellent haze-lowering performance. B1 represents an n-valent chain linking group, L1 and L2 represent a single bond, —O—, —S—, —CO—, —COO—, —OCO—, etc, A1 represents a divalent aromatic hydrocarbon group or a divalent heterocyclic group, A2 represents an aromatic hydrocarbon group, Sp1 represents a single bond, or an alkylene group, Hb1 represents a fluorine-substituted alkyl group, n represents 2 to 6, m represents 0 to 2, and l represents 2 or 3.

PYRAZOLOPYRIMIDINE MACROCYCLES AS INHIBITORS OF HUMAN IMMUNODEFICIENCY VIRUS REPLICATION

The disclosure generally relates to compounds of formula I, including compositions and methods for treating human immunodeficiency virus (HIV) infection. The disclosure provides novel inhibitors of HIV integrase, pharmaceutical compositions containing such compounds, and methods for using these compounds in the treatment of HIV infection.

COMPOUND, HAZE-LOWERING AGENT, LIQUID CRYSTAL COMPOSITION, POLYMER MATERIAL, AND FILM

A compound represented by the following formula (1) has sufficient solubility, a wide usable concentration range, and excellent haze-lowering performance. In the formula, L1 to L6 represent a single bond, -O-, -CO-, -COO-, etc; Sp1 to Sp4 represent a single bond or alkylene of 1 to 10 carbon atoms; A1 and A2 represent trivalent or tetravalent aromatic hydrocarbon or heterocyclic; T represents the following formulae, etc; Hb represent perfluoroalkyl of 2 to 30 carbon atoms; m and n are 2 or 3; and o and p are an integer of 0 or more. ????????(Hb-Sp1-L1-Sp2-L2)m-A1-L3-T-L4-A2-(L5-Sp3-L6-Sp4-Hb)n?????(1)

Use of triazole-ring formation to attach a Ru/TsDPEN complex for asymmetric transfer hydrogenation to a soluble polymer

The cycloaddition of a chiral ligand containing a terminal alkyne to a soluble polymer containing an azide provides a convenient means for the attachment of an asymmetric transfer hydrogenation catalyst to a soluble polymer support. Using these ligands in complexes with Ru(II), gave good results in terms of conversion and enantioselectivity (up to 95% ee) in ketone reduction reactions.

MOLECULAR PROBE PRECURSOR FOR PANCREATIC ISLET IMAGING AND USE OF SAME

A precursor of a molecular probe for imaging of pancreatic islets is a compound expressed as the following formula (I): wherein -V-X represents a substituent on a benzene ring, V represents a bond, R1, or OR1, R1 represent